Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.60 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.60 |
| ▸ | PLK2 | Q9NYY3 | 3/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 8/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | PRKCG | P05129 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | NEK4 | P51957 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.52 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.52 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.52 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.52 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.52 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087350 | 0.89 | RAD52 (0.57) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL1203592 | 0.89 | RAD52 (0.59) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL1203373 | 0.88 | PLK1 (0.59) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL1203142 | 0.88 | RAD52 (0.76) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL4079432 | 0.87 | PLK1 (0.63) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL3672293 | 0.87 | RAD52 (0.64) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL17506101 | 0.87 | PLK1 (0.60) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL3667129 | 0.87 | RAD52 (0.56) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL617777 | 0.87 | PLK1 (0.75) | PLK1PLK3PLK2RAD52BRD4 | |
| SCHEMBL3668298 | 0.84 | PLK1 (0.54) | PLK1PLK3PLK2RAD52BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139892-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| WO-2008113711-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | PLK1 1/4885PLK3 17/4885PLK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.